SL
Silence Therapeutics plc
SLN · NASDAQ
$13.55 -0.99% (-$0.13)
1M -7.95%
Market Cap $640.0M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 1,041.88x
P/B 16.64x
P/E N/A
Growth
22 /100
Declining Rev. growth 68.36%
Book val. growth 41.33%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 51.00%
Net margin 9,755.61%
Op. margin 11,003.00%
Quality
0 /100
Poor ROIC 176.21%
ROE 106.90%
ROA 56.32%
Debt
33 /100
High Debt/Equity -0.00x
Current ratio 7.42x
Int. coverage N/A
Stability
41 /100
Moderate Beta 1.41x
Rev. volatility 90.95%
EPS volatility 11.98%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report